NPLOC4 and cancer: DSF-Cu can also enhance the drug sensitivity of cancer stem cells by interacting with NPL4, potentially disrupting the p97–NPL4–UFD1 pathway and inhibiting p97’s ubiquitinated protein degradation function, thus leading to cell death [198–200].